Jefferies Buy Thesis on TherapeuticsMD (TXMD) Unchanged Following Short Seller Presentation

November 30, 2016 7:58 AM EST
Get Alerts TXMD Hot Sheet
Price: $6.16 --0%

Rating Summary:
    8 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade TXMD Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Jefferies analyst Matthew Andrews reiterated a Buy rating and $18 price target on TherapeuticsMD (NYSE: TXMD) following yesterday's short seller presentation.

Andrews commented, "Shares were down on 11/29/16 due to an investor's short thesis at a conference. Interestingly, thesis largely focuses on competitive dynamics and management criticism and ignored key NT risk for upcoming Ph. III REPLENISH results for TX-001HR. Nothing in the short thesis impacts our expectation for positive REPLENISH data (revenues probability-weighted at 65%) and LT sales potential for Yuvvexy in VVA and '001 in VMS. Buy thesis remains unchanged."

For an analyst ratings summary and ratings history on TherapeuticsMD click here. For more ratings news on TherapeuticsMD click here.

Shares of TherapeuticsMD closed at $5.74 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Short Sales

Related Entities

Jefferies & Co

Add Your Comment